Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07287137 · ClinicalTrials.gov registry record · Phase 4

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

A Phase 4 study of COVID-19 and Influenza, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.

Recruiting
Registry status
Phase 4
Development phase
54
Enrollment target
1
Study location

NCT07287137 is a Phase 4 study of COVID-19 and Influenza that is actively recruiting participants, run by Henry M. Jackson Foundation for the Advancement of Military Medicine. The registered enrollment target is 54 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07287137, a Phase 4 study of COVID-19 and Influenza, is actively recruiting participants, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.

RECRUITING
Registry status
Phase 4
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

Conditions Studied

COVID-19 Influenza Respiratory Virus Respiratory Viruses Respiratory Virus Infection Respiratory Virus Infections

Interventions

  • DRUG Pfizer-BioNTech mRNA COVID-19 vaccine
  • DRUG Novavax recombinant protein vaccine

Study Locations (1)

Maryland

  • Walter Reed National Military Medical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2025-11-12
Est. Completion 2027-09
Phase Phase 4

Sponsor

Henry M. Jackson Foundation for the Advancement of Military Medicine

60 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07287137

The ClinicalTrials.gov registry entry for NCT07287137 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Pfizer-BioNTech mRNA COVID-19 vaccine is the first listed.

NCT07287137 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT07287137 about?

NCT07287137 is a clinical study titled "Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study". CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19...

What is the current status of trial NCT07287137?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2025-11-12. Estimated completion is 2027-09.

What conditions does trial NCT07287137 study?

This clinical trial studies the following conditions: COVID-19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection.

What interventions are being tested in trial NCT07287137?

The interventions under investigation include: Pfizer-BioNTech mRNA COVID-19 vaccine (DRUG), Novavax recombinant protein vaccine (DRUG).

Who is sponsoring clinical trial NCT07287137?

This trial is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07287137 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

Influenza

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.